Duration of Prophylactic Treatment With Oseltamivir: A Randomized Clinical Trial
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 222
- 试验地点
- 1
- 主要终点
- Occurrence of influenza like illness 10 days after oseltamivir prophylactic therapy
研究概览
简要总结
The purpose of this study is to compare the efficacy of 5-day versus 10-day oseltamivir prophylactic treatment in patients who had been exposed to influenza.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years or older
- •exposure to influenza during hospitalization
- •risk factors for influenza complications
- •consent for participation obtained
排除标准
- •younger than 18 years
- •hematological malignancy
- •hospitalized in intensive care unit
- •refusal to participate
研究组 & 干预措施
5 days
oral oseltamivir 75 mg once daily for 5 days post-exposure
干预措施: Oseltamivir Oral Capsule for 5 days post-exposure (Drug)
10 days
oral oseltamivir 75 mg once daily for 10 days post-exposure
干预措施: Oseltamivir Oral Capsule for 10 days post-exposure (Drug)
结局指标
主要结局
Occurrence of influenza like illness 10 days after oseltamivir prophylactic therapy
时间窗: 10 days after oseltamivir prophylactic therapy
Experiencing influenza like illness as self assessed by a patient and/or as assessed by a medical doctor while on prophylaxis with oseltamivir and during the following 10 days.
次要结局
未报告次要终点
研究者
Daša Stupica
Principal Investigator
University Medical Centre Ljubljana